AI-designed vaccine completes first human trial

A vaccine component developed entirely by artificial intelligence has been trialled in 39 people, the first such human study.

• The AI designed a "super-antigen" targeting all coronaviruses, including Covid variants and potential animal-to-human viruses.
• The trial results, published in the Journal of Infection, showed a "modest" immune response, according to the researchers.
• A second trial with approximately 200 participants is planned to further assess the vaccine's ability to train the immune system.
• The Cambridge team is also developing AI-designed vaccines for flu, Ebola, and H5N1 bird flu.